Integra LifeSciences Holdings Corporation (IART)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQ: IART). Investors who purchased Integra securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Integra has violated federal securities laws.
Investigation Details
On May 5, 2025, Integra reported its financial results for the first quarter of 2025. The Company reported a significantly larger loss per share than in the same period of the previous year. The Company also issued full-year earnings guidance, as well as its outlook for Q2 revenues, which are short of consensus estimates. Integra attributed its financial results in part to inventory issues and slower customer ordering patterns. Following this news, Integra stock dropped more than 21.1% on the same day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Integra securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]